Ministeerri Fayyaa Itoophiyaa damee fayyaa biyyattii jabeessuuf mootummaa Ameerika waliin waliigaltee deeggarsaa doolaara ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the ...

Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing ...

Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 ...

PeptiDream (TSE:4587) just logged two meaningful scientific wins, advancing an oral dual IL 17 program into its clinical portfolio and hitting a preclinical siRNA delivery milestone with Alnylam, ...

Vial, a clinical-stage biotech company, today announced growing enthusiasm among metabolic disease KOLs for Vial's INHBE ...

Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

New funding led by Goldcrest Capital and Godfrey Capital to advance lead candidate JUN_01 for type 2 diabetes and obesity to first-in-human studies JUN_01 would be the first ever candidate to ...

Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...